Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin

Observational Study on Evaluation of Glycaemic Control in Patients Using a Modern Insulin - NovoRapid® (Insulin Aspart), NovoMix® 30 (Biphasic Insulin Aspart) or Levemir® (Insulin Detemir) - for Treatment of Diabetes Mellitus

The study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for the treatment type 2 diabetes.

Full acronym for this study: COMMIT - CLEAN SWITCH

Inclusion Criteria:

• Patients with type 2 diabetes
• Patients treated with human soluble insulin, NPH insulin or premixed human insulin
• Patients willing to sign informed consent
• Selection of study participants at the discretion of the physician

Exclusion Criteria:

• Subjects currently being treated with insulin aspart, insulin detemir or biphasic insulin aspart 30
• Subjects who were previously enrolled in this study
• Subjects with a hypersensitivity to insulin aspart, insulin detemir or biphasic insulin aspart 30 or to any of the excipients